spironolactone has been researched along with Cardiomyopathy, Chagas in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status." | 9.12 | A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. ( Botoni, FA; Dantas, JB; Ferreira, CS; Okonko, DO; Oliveira, BM; Pinto, AS; Poole-Wilson, PA; Reis, AM; Ribeiro, AL; Rocha, MO; Tavares, WC; Teixeira, AL; Teixeira, MM, 2007) |
| "In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status." | 5.12 | A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. ( Botoni, FA; Dantas, JB; Ferreira, CS; Okonko, DO; Oliveira, BM; Pinto, AS; Poole-Wilson, PA; Reis, AM; Ribeiro, AL; Rocha, MO; Tavares, WC; Teixeira, AL; Teixeira, MM, 2007) |
| "To evaluate the role of spironolactone in myocardial remodelling in a Chagas cardiomyopathy model." | 3.73 | Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. ( Billate, A; Fernandes, F; Ianni, BM; Mady, C; Martins, DG; Neto, EC; Ramires, FJ; Salemi, VM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramires, FJ | 1 |
| Salemi, VM | 1 |
| Ianni, BM | 1 |
| Fernandes, F | 1 |
| Martins, DG | 1 |
| Billate, A | 1 |
| Neto, EC | 1 |
| Mady, C | 1 |
| Botoni, FA | 1 |
| Poole-Wilson, PA | 1 |
| Ribeiro, AL | 1 |
| Okonko, DO | 1 |
| Oliveira, BM | 1 |
| Pinto, AS | 1 |
| Teixeira, MM | 1 |
| Teixeira, AL | 1 |
| Reis, AM | 1 |
| Dantas, JB | 1 |
| Ferreira, CS | 1 |
| Tavares, WC | 1 |
| Rocha, MO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy[NCT01557140] | Phase 4 | 42 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for spironolactone and Cardiomyopathy, Chagas
| Article | Year |
|---|---|
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chaga | 2007 |
1 other study available for spironolactone and Cardiomyopathy, Chagas
| Article | Year |
|---|---|
Aldosterone antagonism in an inflammatory state: evidence for myocardial protection.
Topics: Aldosterone; Animals; Cardiotonic Agents; Chagas Cardiomyopathy; Collagen; Cricetinae; Disease Model | 2006 |